(Q30627873)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

postmenopausal osteoporosis

1 March 2020

main subject

osteoporosis

0 references

1 reference

Sherri-Ann M Burnett-Bowie

inferred from title

author

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Joy N Tsai

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Alexander V Uihlein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Hang Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ruchit Kumbhani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Erica Siwila-Sackman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Elizabeth A McKay

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Robert M Neer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Benjamin Z Leder

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

15 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

382

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

9886

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

50-56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density

1 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

The use of combination therapy in the treatment of postmenopausal osteoporosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Mechanism of action of bisphosphonates

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

An assessment tool for predicting fracture risk in postmenopausal women

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083737

Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.

25 November 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

Efficacy and safety of ibandronate given by intravenous injection once every 3 months

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

In vivo effects of bisphosphonates on the osteoclast mevalonate pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960856-9

7 January 2021

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23683600

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1016/S0140-6736(13)60856-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference